Affymetrix, Inc.
AFFX
NASDAQ14.01
USD
-0.01
- -
Affymetrix, Inc.
AFFX
(NASDAQ)
Recent
price
14.01
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Affymetrix, Inc. Affymetrix, Inc. (AFFX) develops and commercializes genetic analysis tools and systems, specializing in microarray technologies for gene expression, genotyping, and cytogenetic applications; its core offerings include the GeneChip brand platform for gene expression and genotyping products such as CytoScan and OncoScan assays, QuantiGene singleplex and multiplex assays for research and translational medicine, GeneTitan instrument systems for array processing, life science reagents like ExoSAP-IT and HotStart-IT enzymes, purification kits, biochemicals, and eBioscience products encompassing antibodies, reagents, flow cytometry tools, immunoassays, and protein-based analyses for cellular analysis. The company operates in two primary segments, Affymetrix Core focusing on genetic analysis systems for life sciences, AgBio, and diagnostics, and eBioscience dedicated to flow cytometry, microscopic imaging, and multiplex assays; it serves genomic research centers, academic institutions, government and private laboratories, pharmaceutical, biotechnology, and diagnostic firms through direct sales and third-party distributors primarily in the United States, Europe, Asia Pacific including China, Mexico, India, Brazil, and the Middle East. Founded in 1991 and spun off from Affymax Research Institute in 1993 with headquarters in Santa Clara, California, Affymetrix pioneered DNA microarray fabrication using semiconductor techniques, launching its first GeneChip HIV genotyping product in 1994 and going public in 1996. Recent major developments include the acquisition of Genetic MicroSystems and Neomorphic in 2000 for microarray scanners and bioinformatics, ParAllele Bioscience for SNP genotyping, Panomics and USB/Anatrace in 2008 for mid-plex assays and reagents, eBioscience in 2012 for flow cytometry expansion, and crucially, its acquisition by Thermo Fisher Scientific Inc. Thermo Fisher Scientific Inc. in 2016 for approximately $1.3 billion, after which Affymetrix integrates into Thermo Fisher's Life Sciences Solutions segment as the Applied Biosystems microarray brand, with FDA clearance of the CytoScan Dx Assay in 2014 for postnatal genetic testing of developmental disorders; these changes enhance its antibody portfolio for flow cytometry, single-cell biology, immunotherapy, reproductive health, and agrigenomics while leveraging Thermo Fisher's global scale for broader distribution and synergies exceeding $70 million.